Skip to content

TriangleGet started

← Full study record

NCT02003924 · OUTCOME

Number of Participants With European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Usual Activities Domain Score

Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer · Source last updated 2026-01-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177

What was measured

EQ-5D-5L is a standardized instrument that measures health-related quality of life for men with prostate cancer. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. Number of participants with various responses to the usual activities questionnaire are reported.

Analysis population: The ITT population was defined as all participants randomly assigned to study treatment and was based on randomized treatment assignment regardless of whether or not treatment was administered. Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified categories.

Groups in this outcome

Enzalutamide 160 mg

Participants received 4 capsules of Enzalutamide 40 mg each (total dose 160 mg per day) orally, once daily in double-blind and open-label phase (up to a maximum of 68.8 months) until radiographic progression. Participants after last dose of study drug, were followed up for safety up to 30 days, and were long term followed up (for survival status and new prostate cancer therapies) from last dose to the death date or last known survival date.

Placebo

Participants received 4 capsules of placebo (matched to Enzalutamide) orally, once daily in double blind phase (up to a maximum of 51.3 months) until radiographic progression. Participants were given an opportunity to switch to open-label enzalutamide after completion of double blind phase. Participants after last dose of study drug, were followed up for safety up to 30 days and were long term followed up (for survival status and new prostate cancer therapies) to the death date or last known survival date.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	933
Placebo	468

Reported measurements

Baseline:no problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	884
Placebo	439

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	646	Not reported	Not reported	Not reported	Not reported
Placebo	356	Not reported	Not reported	Not reported	Not reported

Baseline:slight problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	884
Placebo	439

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	167	Not reported	Not reported	Not reported	Not reported
Placebo	64	Not reported	Not reported	Not reported	Not reported

Baseline:moderate problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	884
Placebo	439

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	56	Not reported	Not reported	Not reported	Not reported
Placebo	14	Not reported	Not reported	Not reported	Not reported

Baseline:severe problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	884
Placebo	439

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	10	Not reported	Not reported	Not reported	Not reported
Placebo	5	Not reported	Not reported	Not reported	Not reported

Baseline:unable to do usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	884
Placebo	439

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	5	Not reported	Not reported	Not reported	Not reported
Placebo	0	Not reported	Not reported	Not reported	Not reported

Week 17:no problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	840
Placebo	419

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	571	Not reported	Not reported	Not reported	Not reported
Placebo	305	Not reported	Not reported	Not reported	Not reported

Week 17:slight problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	840
Placebo	419

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	181	Not reported	Not reported	Not reported	Not reported
Placebo	89	Not reported	Not reported	Not reported	Not reported

Week 17:moderate problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	840
Placebo	419

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	60	Not reported	Not reported	Not reported	Not reported
Placebo	24	Not reported	Not reported	Not reported	Not reported

Week 17:severe problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	840
Placebo	419

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	21	Not reported	Not reported	Not reported	Not reported
Placebo	0	Not reported	Not reported	Not reported	Not reported

Week 17:unable to do usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	840
Placebo	419

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	7	Not reported	Not reported	Not reported	Not reported
Placebo	1	Not reported	Not reported	Not reported	Not reported

Week 33:no problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	738
Placebo	342

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	474	Not reported	Not reported	Not reported	Not reported
Placebo	249	Not reported	Not reported	Not reported	Not reported

Week 33:slight problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	738
Placebo	342

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	170	Not reported	Not reported	Not reported	Not reported
Placebo	68	Not reported	Not reported	Not reported	Not reported

Week 33:moderate problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	738
Placebo	342

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	68	Not reported	Not reported	Not reported	Not reported
Placebo	18	Not reported	Not reported	Not reported	Not reported

Week 33:severe problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	738
Placebo	342

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	21	Not reported	Not reported	Not reported	Not reported
Placebo	7	Not reported	Not reported	Not reported	Not reported

Week 33:unable to do usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	738
Placebo	342

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	5	Not reported	Not reported	Not reported	Not reported
Placebo	0	Not reported	Not reported	Not reported	Not reported

Week 49:no problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	635
Placebo	250

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	418	Not reported	Not reported	Not reported	Not reported
Placebo	185	Not reported	Not reported	Not reported	Not reported

Week 49:slight problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	635
Placebo	250

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	137	Not reported	Not reported	Not reported	Not reported
Placebo	43	Not reported	Not reported	Not reported	Not reported

Week 49:moderate problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	635
Placebo	250

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	55	Not reported	Not reported	Not reported	Not reported
Placebo	14	Not reported	Not reported	Not reported	Not reported

Week 49:severe problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	635
Placebo	250

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	20	Not reported	Not reported	Not reported	Not reported
Placebo	6	Not reported	Not reported	Not reported	Not reported

Week 49:unable to do usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	635
Placebo	250

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	5	Not reported	Not reported	Not reported	Not reported
Placebo	2	Not reported	Not reported	Not reported	Not reported

Week 65:no problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	536
Placebo	193

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	338	Not reported	Not reported	Not reported	Not reported
Placebo	136	Not reported	Not reported	Not reported	Not reported

Week 65:slight problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	536
Placebo	193

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	123	Not reported	Not reported	Not reported	Not reported
Placebo	42	Not reported	Not reported	Not reported	Not reported

Week 65:moderate problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	536
Placebo	193

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	60	Not reported	Not reported	Not reported	Not reported
Placebo	11	Not reported	Not reported	Not reported	Not reported

Week 65:severe problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	536
Placebo	193

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	5	Not reported	Not reported	Not reported	Not reported
Placebo	4	Not reported	Not reported	Not reported	Not reported

Week 65:unable to do usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	536
Placebo	193

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	10	Not reported	Not reported	Not reported	Not reported
Placebo	0	Not reported	Not reported	Not reported	Not reported

Week 81:no problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	435
Placebo	148

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	267	Not reported	Not reported	Not reported	Not reported
Placebo	106	Not reported	Not reported	Not reported	Not reported

Week 81:slight problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	435
Placebo	148

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	105	Not reported	Not reported	Not reported	Not reported
Placebo	29	Not reported	Not reported	Not reported	Not reported

Week 81:moderate problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	435
Placebo	148

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	49	Not reported	Not reported	Not reported	Not reported
Placebo	7	Not reported	Not reported	Not reported	Not reported

Week 81:severe problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	435
Placebo	148

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	10	Not reported	Not reported	Not reported	Not reported
Placebo	3	Not reported	Not reported	Not reported	Not reported

Week 81:unable to do usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	435
Placebo	148

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	4	Not reported	Not reported	Not reported	Not reported
Placebo	3	Not reported	Not reported	Not reported	Not reported

Week 97:no problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	365
Placebo	95

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	224	Not reported	Not reported	Not reported	Not reported
Placebo	69	Not reported	Not reported	Not reported	Not reported

Week 97:slight problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	365
Placebo	95

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	90	Not reported	Not reported	Not reported	Not reported
Placebo	16	Not reported	Not reported	Not reported	Not reported

Week 97:moderate problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	365
Placebo	95

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	39	Not reported	Not reported	Not reported	Not reported
Placebo	8	Not reported	Not reported	Not reported	Not reported

Week 97:severe problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	365
Placebo	95

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	9	Not reported	Not reported	Not reported	Not reported
Placebo	0	Not reported	Not reported	Not reported	Not reported

Week 97:unable to do usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	365
Placebo	95

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	3	Not reported	Not reported	Not reported	Not reported
Placebo	2	Not reported	Not reported	Not reported	Not reported

Week 113:no problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	275
Placebo	73

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	165	Not reported	Not reported	Not reported	Not reported
Placebo	47	Not reported	Not reported	Not reported	Not reported

Week 113:slight problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	275
Placebo	73

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	69	Not reported	Not reported	Not reported	Not reported
Placebo	16	Not reported	Not reported	Not reported	Not reported

Week 113:moderate problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	275
Placebo	73

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	33	Not reported	Not reported	Not reported	Not reported
Placebo	6	Not reported	Not reported	Not reported	Not reported

Week 113:severe problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	275
Placebo	73

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	5	Not reported	Not reported	Not reported	Not reported
Placebo	3	Not reported	Not reported	Not reported	Not reported

Week 113:unable to do usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	275
Placebo	73

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	3	Not reported	Not reported	Not reported	Not reported
Placebo	1	Not reported	Not reported	Not reported	Not reported

Week 129: Week :no problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	193
Placebo	41

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	108	Not reported	Not reported	Not reported	Not reported
Placebo	30	Not reported	Not reported	Not reported	Not reported

Week 129 :slight problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	193
Placebo	41

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	56	Not reported	Not reported	Not reported	Not reported
Placebo	8	Not reported	Not reported	Not reported	Not reported

Week 129:moderate problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	193
Placebo	41

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	26	Not reported	Not reported	Not reported	Not reported
Placebo	3	Not reported	Not reported	Not reported	Not reported

Week 129:severe problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	193
Placebo	41

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	3	Not reported	Not reported	Not reported	Not reported
Placebo	0	Not reported	Not reported	Not reported	Not reported

Week 129:unable to do usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	193
Placebo	41

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	0	Not reported	Not reported	Not reported	Not reported
Placebo	0	Not reported	Not reported	Not reported	Not reported

Week 145:no problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	116
Placebo	21

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	67	Not reported	Not reported	Not reported	Not reported
Placebo	14	Not reported	Not reported	Not reported	Not reported

Week 145:slight problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	116
Placebo	21

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	35	Not reported	Not reported	Not reported	Not reported
Placebo	4	Not reported	Not reported	Not reported	Not reported

Week 145:moderate problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	116
Placebo	21

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	11	Not reported	Not reported	Not reported	Not reported
Placebo	2	Not reported	Not reported	Not reported	Not reported

Week 145:severe problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	116
Placebo	21

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	3	Not reported	Not reported	Not reported	Not reported
Placebo	1	Not reported	Not reported	Not reported	Not reported

Week 145:unable to do usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	116
Placebo	21

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	0	Not reported	Not reported	Not reported	Not reported
Placebo	0	Not reported	Not reported	Not reported	Not reported

Week 161:no problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	40
Placebo	8

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	23	Not reported	Not reported	Not reported	Not reported
Placebo	5	Not reported	Not reported	Not reported	Not reported

Week 161:slight problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	40
Placebo	8

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	9	Not reported	Not reported	Not reported	Not reported
Placebo	2	Not reported	Not reported	Not reported	Not reported

Week 161:moderate problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	40
Placebo	8

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	5	Not reported	Not reported	Not reported	Not reported
Placebo	1	Not reported	Not reported	Not reported	Not reported

Week 161:severe problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	40
Placebo	8

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	2	Not reported	Not reported	Not reported	Not reported
Placebo	0	Not reported	Not reported	Not reported	Not reported

Week 161:unable to do usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	40
Placebo	8

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	1	Not reported	Not reported	Not reported	Not reported
Placebo	0	Not reported	Not reported	Not reported	Not reported

Week 177:no problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	6
Placebo	1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	3	Not reported	Not reported	Not reported	Not reported
Placebo	0	Not reported	Not reported	Not reported	Not reported

Week 177:slight problems doing usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	6
Placebo	1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	2	Not reported	Not reported	Not reported	Not reported
Placebo	1	Not reported	Not reported	Not reported	Not reported

Week 177:moderate problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	6
Placebo	1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	1	Not reported	Not reported	Not reported	Not reported
Placebo	0	Not reported	Not reported	Not reported	Not reported

Week 177:severe problems

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	6
Placebo	1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	0	Not reported	Not reported	Not reported	Not reported
Placebo	0	Not reported	Not reported	Not reported	Not reported

Week 177:unable to do usual activities

Analysis denominator · Participants

Group	Source count
Enzalutamide 160 mg	6
Placebo	1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Enzalutamide 160 mg	0	Not reported	Not reported	Not reported	Not reported
Placebo	0	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
646
group Id
OG001
value
356
denoms
counts
group Id
OG000
value
884
group Id
OG001
value
439
units
Participants
title
Baseline:no problems doing usual activities
categories
measurements
group Id
OG000
value
167
group Id
OG001
value
64
denoms
counts
group Id
OG000
value
884
group Id
OG001
value
439
units
Participants
title
Baseline:slight problems doing usual activities
categories
measurements
group Id
OG000
value
56
group Id
OG001
value
14
denoms
counts
group Id
OG000
value
884
group Id
OG001
value
439
units
Participants
title
Baseline:moderate problems
categories
measurements
group Id
OG000
value
10
group Id
OG001
value
5
denoms
counts
group Id
OG000
value
884
group Id
OG001
value
439
units
Participants
title
Baseline:severe problems
categories
measurements
group Id
OG000
value
5
group Id
OG001
value
0
denoms
counts
group Id
OG000
value
884
group Id
OG001
value
439
units
Participants
title
Baseline:unable to do usual activities
categories
measurements
group Id
OG000
value
571
group Id
OG001
value
305
denoms
counts
group Id
OG000
value
840
group Id
OG001
value
419
units
Participants
title
Week 17:no problems doing usual activities
categories
measurements
group Id
OG000
value
181
group Id
OG001
value
89
denoms
counts
group Id
OG000
value
840
group Id
OG001
value
419
units
Participants
title
Week 17:slight problems doing usual activities
categories
measurements
group Id
OG000
value
60
group Id
OG001
value
24
denoms
counts
group Id
OG000
value
840
group Id
OG001
value
419
units
Participants
title
Week 17:moderate problems
categories
measurements
group Id
OG000
value
21
group Id
OG001
value
0
denoms
counts
group Id
OG000
value
840
group Id
OG001
value
419
units
Participants
title
Week 17:severe problems
categories
measurements
group Id
OG000
value
7
group Id
OG001
value
1
denoms
counts
group Id
OG000
value
840
group Id
OG001
value
419
units
Participants
title
Week 17:unable to do usual activities
categories
measurements
group Id
OG000
value
474
group Id
OG001
value
249
denoms
counts
group Id
OG000
value
738
group Id
OG001
value
342
units
Participants
title
Week 33:no problems doing usual activities
categories
measurements
group Id
OG000
value
170
group Id
OG001
value
68
denoms
counts
group Id
OG000
value
738
group Id
OG001
value
342
units
Participants
title
Week 33:slight problems doing usual activities

denoms

counts
group Id
OG000
value
933
group Id
OG001
value
468
units
Participants

description

EQ-5D-5L is a standardized instrument that measures health-related quality of life for men with prostate cancer. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. Number of participants with various responses to the usual activities questionnaire are reported.

groups

description
Participants received 4 capsules of Enzalutamide 40 mg each (total dose 160 mg per day) orally, once daily in double-blind and open-label phase (up to a maximum of 68.8 months) until radiographic progression. Participants after last dose of study drug, were followed up for safety up to 30 days, and were long term followed up (for survival status and new prostate cancer therapies) from last dose to the death date or last known survival date.
id
OG000
title
Enzalutamide 160 mg
description
Participants received 4 capsules of placebo (matched to Enzalutamide) orally, once daily in double blind phase (up to a maximum of 51.3 months) until radiographic progression. Participants were given an opportunity to switch to open-label enzalutamide after completion of double blind phase. Participants after last dose of study drug, were followed up for safety up to 30 days and were long term followed up (for survival status and new prostate cancer therapies) to the death date or last known survival date.
id
OG001
title
Placebo

param Type

NUMBER

population Description

The ITT population was defined as all participants randomly assigned to study treatment and was based on randomized treatment assignment regardless of whether or not treatment was administered. Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified categories.

reporting Status

POSTED

time Frame

Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177

title

Number of Participants With European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Usual Activities Domain Score

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice